Revance rises on FDA approval for treatment of painful neck muscle condition

Revance Therapeutics

14/08/2023 13:36

** Shares of Revance Therapeutics  RVNC.O  rise 7.8% to
$20.38 premarket
    ** U.S. Food and Drug Administration (FDA) approved expanded
use for co's anti-wrinkle injection, Daxxify, to treat a painful
neck muscle condition 
    ** The condition called cervical dystonia involves
involuntary contraction of neck muscles and causes the head to
twist to one side
    ** Co says it would share more information on the pricing
when the product is launched commercially
    ** Up to last close, shares up 2.4% YTD

 (Reporting by Christy Santhosh in Bengaluru)
 ((Christy.santhosh@thomsonreuters.com))